Phathom Pharmaceuticals, Inc. PHAT
6.28 USD +0.84 (+15.34%)
At closeNov 12, 2026, 4:25 AM EST
6.01 -0.27 -4.30%
Pre-market · Nov 12, 4:25 AM ET
5.41 Day range 6.32
5.02 52-week range 18.31
- YTD
- -62.15%
- 1 year
- -56.27%
News
zacks.com Implied Volatility Surging for Phathom Pharmaceuticals Stock Options Investors need to pay close attention to PHAT stock based on the movements in the options market lately.
benzinga.com Phathom Pharmaceuticals Announces $0 Payment From Eligible Commercially Insured Patients For VOQUEZNA Tablets Through BlinkRx Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal diseases, today announced that eligible…
benzinga.com Phathom Pharmaceuticals Q3 2026 Earnings Call Transcript Phathom Pharmaceuticals (NASDAQ:PHAT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Phathom Pharmaceuticals Affirms FY2026 Sales Guidance of $310.000M-$325.000M vs $314.842M Est Phathom Pharmaceuticals (NASDAQ:PHAT) affirms FY2026 sales outlook from $310.000 million-$325.000 million to $310.000 million-$325.000 million vs $314.842 million estimate.
benzinga.com Phathom Pharmaceuticals Q3 Adj. EPS $0.04 Beats $0.02 Estimate, Sales $84.722M Miss $85.096M Estimate Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.02 by 100 percent. This is a 126.67 percent increase over losses…- benzinga.com Phathom Pharmaceuticals To Present New Cost-Effectiveness Data For VOQUEZNA At The American College Of Gastroenterology Meeting, October 9-14; New analysis projects VOQUEZNA® (vonoprazan) to provide meaningful economic value and be cost-effective vs. proton pump inhibitors (PPIs) for adults with Erosive GERD, with potential cost savings at…